Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL12352425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL1821276 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4522263 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL13362239 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2228590 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403819 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL19107495 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-9885082-B2 | Embodiments of a probe and method for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2017201585-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | GENEA IP HOLDINGS PTY LTD (AU) | 2017-11-30 | — | — | WO | disclosed |
| US-9814670-B2 | Cosmetic compositions | MARY KAY INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-7741473-B2 | Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7544518-B2 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544518-B2 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| US-7414036-B2 | Compounds useful as A3 adenosine receptor agonists | MUSCAGEN LIMITED (GB) | 2008-08-19 | — | — | US | disclosed |
| US-20070249556-A1 | METHOD OF TREATING INFLAMMATION | INSPIRE PHARMACEUTICALS, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | disclosed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | ADORA3 642/4885ADORA2A 211/4885ADORA2B 565/4885 |
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | ADORA3, ADORA2B, P2RX3 | ADORA3 1/4885ADORA2A 9/4885ADORA2B 2/4885 |
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | ADORA3 239/4885ADORA2A 405/4885ADORA2B 194/4885 |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | ADORA3 239/4885ADORA2A 405/4885ADORA2B 194/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | ADORA3 704/4885ADORA2A 306/4885ADORA2B 537/4885 |
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | ADORA3 239/4885ADORA2A 405/4885ADORA2B 194/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA3 739/4885ADORA2A 368/4885ADORA2B 686/4885 |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-20070249556-A1 | METHOD OF TREATING INFLAMMATION | MIF, CCL2, TNF | ADORA3 690/4885ADORA2A 625/4885ADORA2B 325/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | ADORA3 704/4885ADORA2A 306/4885ADORA2B 537/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA3 739/4885ADORA2A 368/4885ADORA2B 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.